| . | Complications (no. of cases) . | ||||
|---|---|---|---|---|---|
| Treatment: no. of cases (%) for each complication . | Vascular compromise (n = 18) . | Infection (n = 5) . | Allergies (n = 3) . | Neuropathy (n = 2) . | Acute conjunctivitisa (n = 1) . |
| Hyaluronidase | 17 (94.44%) | 4 (80.00%) | 2 (66.67%) | ||
| Prostaglandin | 9 (50.00%) | ||||
| NSAIDs | 6 (33.33%) | ||||
| Antibiotics | 5 (27.78%) | 5 (100.00%) | |||
| Corticosteroid | 3 (16.67%) | 1 (20.00%) | 2 (66.67%) | 1 (50.00%) | |
| Vitamin B12 preparations | 2 (100.00%) | ||||
| Synthetic antibacterial | 1 (20.00%) | ||||
| Antihistamine | 1 (20.00%) | 1 (33.33%) | |||
| H2-receptor antagonist | 1 (20.00%) | ||||
| . | Complications (no. of cases) . | ||||
|---|---|---|---|---|---|
| Treatment: no. of cases (%) for each complication . | Vascular compromise (n = 18) . | Infection (n = 5) . | Allergies (n = 3) . | Neuropathy (n = 2) . | Acute conjunctivitisa (n = 1) . |
| Hyaluronidase | 17 (94.44%) | 4 (80.00%) | 2 (66.67%) | ||
| Prostaglandin | 9 (50.00%) | ||||
| NSAIDs | 6 (33.33%) | ||||
| Antibiotics | 5 (27.78%) | 5 (100.00%) | |||
| Corticosteroid | 3 (16.67%) | 1 (20.00%) | 2 (66.67%) | 1 (50.00%) | |
| Vitamin B12 preparations | 2 (100.00%) | ||||
| Synthetic antibacterial | 1 (20.00%) | ||||
| Antihistamine | 1 (20.00%) | 1 (33.33%) | |||
| H2-receptor antagonist | 1 (20.00%) | ||||
Removal of hyaluronic acid by another ophthalmologist.
| . | Complications (no. of cases) . | ||||
|---|---|---|---|---|---|
| Treatment: no. of cases (%) for each complication . | Vascular compromise (n = 18) . | Infection (n = 5) . | Allergies (n = 3) . | Neuropathy (n = 2) . | Acute conjunctivitisa (n = 1) . |
| Hyaluronidase | 17 (94.44%) | 4 (80.00%) | 2 (66.67%) | ||
| Prostaglandin | 9 (50.00%) | ||||
| NSAIDs | 6 (33.33%) | ||||
| Antibiotics | 5 (27.78%) | 5 (100.00%) | |||
| Corticosteroid | 3 (16.67%) | 1 (20.00%) | 2 (66.67%) | 1 (50.00%) | |
| Vitamin B12 preparations | 2 (100.00%) | ||||
| Synthetic antibacterial | 1 (20.00%) | ||||
| Antihistamine | 1 (20.00%) | 1 (33.33%) | |||
| H2-receptor antagonist | 1 (20.00%) | ||||
| . | Complications (no. of cases) . | ||||
|---|---|---|---|---|---|
| Treatment: no. of cases (%) for each complication . | Vascular compromise (n = 18) . | Infection (n = 5) . | Allergies (n = 3) . | Neuropathy (n = 2) . | Acute conjunctivitisa (n = 1) . |
| Hyaluronidase | 17 (94.44%) | 4 (80.00%) | 2 (66.67%) | ||
| Prostaglandin | 9 (50.00%) | ||||
| NSAIDs | 6 (33.33%) | ||||
| Antibiotics | 5 (27.78%) | 5 (100.00%) | |||
| Corticosteroid | 3 (16.67%) | 1 (20.00%) | 2 (66.67%) | 1 (50.00%) | |
| Vitamin B12 preparations | 2 (100.00%) | ||||
| Synthetic antibacterial | 1 (20.00%) | ||||
| Antihistamine | 1 (20.00%) | 1 (33.33%) | |||
| H2-receptor antagonist | 1 (20.00%) | ||||
Removal of hyaluronic acid by another ophthalmologist.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
